BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
BioAge Labs, Inc.NASDAQ: BIOA
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow declines year over year
Q1 FY2026 investing cash flow of $46.75M (cash outflow) fell 40.1% year over year, behind the -18.3% change in trailing-twelve-month investing cash flow. Sequentially, it rose 224.0% from the prior quarter. Over 3 fiscal years it compounded at +874.1% a year.
Context
- Investing cash flow amounted to 1058.5% of revenue in FY2025.
- Investing cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.1% toward the trailing-twelve-month pace of -18.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (95.22M) USD
- Year-over-year change
- -25915.3%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (95.22M) | -25915.3% |
| FY2024 | 2024-12-31 | (366K) | -37.6% |
| FY2023 | 2023-12-31 | (266K) | -158.3% |
| FY2022 | 2022-12-31 | (103K) | — |
Investing Cash Flow vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -18.3% is the 5th highest of 9, against a peer median of -20.5%.
- Investing cash flow amounts to 620.2% of revenue for BIOA, versus a peer median of 22.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $132.92M USD | +56.5% | — | — | |
| LTM Mar 2026 | $82.35M USD | -63.1% | +6.7% | 212.8% | |
| LTM Mar 2026 | CA$72.62M CAD | +379.1% | +39.2% | 23.4% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $63.98M USD | -18.3% | +874.1% | 620.2% |
| LTM Mar 2026 | $59.8M USD | +0.1% | -3.4% | — | |
| LTM Mar 2026 | CA$19.39M CAD | -59.4% | — | 6.2% | |
| LTM Mar 2026 | $8.72M USD | +137.1% | — | 20.9% | |
| LTM Mar 2026 | $3.09M USD | — | — | 2.3% | |
| LTM Mar 2026 | $1.48M USD | -96.9% | +22.7% | — | |
| LTM Mar 2026 | $831K USD | -41.0% | — | 41.2% | |
| Peer median (excluding BIOA) | — | -20.5% | +14.7% | 22.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.